IOVA – Iovance Biotherapeutics, Inc.
IOVA — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
32.74
Margin Of Safety %
Put/Call OI Ratio
0.31
EPS Next Q Diff
0.05
EPS Last/This Y
0.59
EPS This/Next Y
0.26
Price
3.52
Target Price
9
Analyst Recom
1.64
Performance Q
22.3
Upside
-1,216.8%
Beta
0.74
Ticker: IOVA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | IOVA | 3.82 | 0.20 | 0.13 | 176182 |
| 2026-03-02 | IOVA | 3.8 | 0.17 | 1.20 | 161634 |
| 2026-03-03 | IOVA | 3.74 | 0.18 | 0.18 | 165637 |
| 2026-03-04 | IOVA | 4.24 | 0.18 | 0.08 | 166794 |
| 2026-03-05 | IOVA | 4.55 | 0.18 | 0.02 | 166696 |
| 2026-03-06 | IOVA | 5.12 | 0.18 | 0.43 | 170888 |
| 2026-03-09 | IOVA | 5.41 | 0.25 | 0.49 | 184050 |
| 2026-03-10 | IOVA | 5.2 | 0.27 | 0.47 | 188105 |
| 2026-03-11 | IOVA | 4.82 | 0.29 | 0.32 | 194720 |
| 2026-03-12 | IOVA | 4.07 | 0.30 | 0.28 | 199230 |
| 2026-03-13 | IOVA | 4.07 | 0.30 | 0.31 | 199230 |
| 2026-03-17 | IOVA | 3.89 | 0.31 | 0.18 | 204613 |
| 2026-03-18 | IOVA | 3.78 | 0.31 | 0.16 | 206337 |
| 2026-03-19 | IOVA | 3.87 | 0.31 | 0.43 | 207631 |
| 2026-03-20 | IOVA | 3.7 | 0.31 | 0.07 | 208416 |
| 2026-03-23 | IOVA | 3.62 | 0.31 | 0.20 | 172563 |
| 2026-03-24 | IOVA | 3.61 | 0.31 | 0.29 | 176477 |
| 2026-03-25 | IOVA | 3.74 | 0.31 | 0.09 | 182664 |
| 2026-03-26 | IOVA | 3.69 | 0.31 | 0.34 | 186304 |
| 2026-03-27 | IOVA | 3.52 | 0.31 | 0.50 | 187510 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | IOVA | 3.88 | 61.2 | -432.9 | -0.50 |
| 2026-03-02 | IOVA | 3.80 | 61.2 | 169.3 | -0.50 |
| 2026-03-03 | IOVA | 3.74 | 61.2 | 169.1 | -0.50 |
| 2026-03-04 | IOVA | 4.25 | 61.2 | 112.1 | -0.50 |
| 2026-03-05 | IOVA | 4.60 | 61.2 | 127.3 | -0.50 |
| 2026-03-06 | IOVA | 5.14 | 61.2 | 117.9 | -0.50 |
| 2026-03-09 | IOVA | 5.41 | 61.2 | 136.7 | -0.50 |
| 2026-03-10 | IOVA | 5.20 | 61.2 | 162.2 | -0.50 |
| 2026-03-11 | IOVA | 4.83 | 61.2 | 171.4 | -0.50 |
| 2026-03-12 | IOVA | 4.07 | 61.2 | 196.7 | -0.50 |
| 2026-03-13 | IOVA | 3.96 | 61.2 | 159.5 | -0.50 |
| 2026-03-17 | IOVA | 3.89 | 61.2 | 162.0 | -0.50 |
| 2026-03-18 | IOVA | 3.77 | 61.2 | -120.0 | -0.50 |
| 2026-03-19 | IOVA | 3.86 | 61.2 | 141.2 | -0.50 |
| 2026-03-20 | IOVA | 3.69 | 61.2 | 161.9 | -0.50 |
| 2026-03-23 | IOVA | 3.62 | 61.2 | 155.4 | -0.50 |
| 2026-03-24 | IOVA | 3.61 | 61.2 | 150.2 | -0.50 |
| 2026-03-25 | IOVA | 3.74 | 61.2 | 138.6 | -0.50 |
| 2026-03-26 | IOVA | 3.69 | 61.2 | 153.8 | -0.50 |
| 2026-03-27 | IOVA | 3.52 | 61.2 | 163.1 | -0.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | IOVA | 0.00 | 15.17 | 37.40 |
| 2026-03-02 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-03 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-04 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-05 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-06 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-09 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-10 | IOVA | 0.00 | 15.14 | 37.37 |
| 2026-03-11 | IOVA | 0.00 | 15.14 | 37.26 |
| 2026-03-12 | IOVA | 0.00 | 15.14 | 37.26 |
| 2026-03-13 | IOVA | 0.00 | 15.14 | 37.26 |
| 2026-03-17 | IOVA | 0.00 | 15.21 | 37.26 |
| 2026-03-18 | IOVA | 0.00 | 15.21 | 37.26 |
| 2026-03-19 | IOVA | 0.00 | 15.21 | 37.26 |
| 2026-03-20 | IOVA | 0.00 | 15.21 | 37.26 |
| 2026-03-23 | IOVA | 0.00 | 15.23 | 37.26 |
| 2026-03-24 | IOVA | 0.00 | 15.23 | 37.26 |
| 2026-03-25 | IOVA | 0.00 | 15.23 | 32.74 |
| 2026-03-26 | IOVA | 0.00 | 15.23 | 32.74 |
| 2026-03-27 | IOVA | 0.00 | 15.23 | 32.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.13
Insider Transactions
Institutional Transactions
15.23
Beta
0.74
Average Sales Estimate Current Quarter
79
Average Sales Estimate Next Quarter
88
Fair Value
Quality Score
29
Growth Score
28
Sentiment Score
46
Actual DrawDown %
89.7
Max Drawdown 5-Year %
-95
Target Price
9
P/E
Forward P/E
PEG
P/S
5.49
P/B
2.07
P/Free Cash Flow
EPS
-1.12
Average EPS Est. Cur. Y
-0.5
EPS Next Y. (Est.)
-0.24
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-148.41
Relative Volume
0.56
Return on Equity vs Sector %
-83.3
Return on Equity vs Industry %
-67.1
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.11
EBIT Estimation
163.1
◆
IOVA
Healthcare
$3.51
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
44.7
Range 1M
5.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
54%
EPS NY
55.7%
52W%
47.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+156.4% upside
Upside
+156.4%
Quality
29
Iovance Biotherapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 975
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA
Latest News
—
Caricamento notizie per IOVA…
stock quote shares IOVA – Iovance Biotherapeutics, Inc. Stock Price stock today
news today IOVA – Iovance Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IOVA – Iovance Biotherapeutics, Inc. yahoo finance google finance
stock history IOVA – Iovance Biotherapeutics, Inc. invest stock market
stock prices IOVA premarket after hours
ticker IOVA fair value insiders trading